In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for Zoetis Inc. ZTS. These include:
- June 25, 2015 - Tax matters agreement with Pfizer expires. ZTS gets more flexibility in selling itself / doing large scale M&A or share buybacks
- April 2015 - Uptake in Apoquel revenues as supply issues expected to be resolved and can launch in new markets
- Mid 2015 - Expected conditional license for a recently filed with USDA new monoclonal Ab for Atopic Dermatitis in dogs (likely to be positioned as 2nd line treatment after Apoquel)
- 2015 - Completion of separating from PFE (rebuilding IT infrastructure - SAP)
- 2015 - Progress of PEDv vaccine launch (protects piglets but sows are vaccinated)
- 2015 - Progress of Improvest/Improvac (pigs) US sales
- 2015-6 - Gradual tax optimization, potential changes in capital structure (more debt)
- 2016 - Monitor sales of Sarolaner - oral anti-tick and flea; see if could be differentiated from competition and market share
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in